A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
OncoC4, Inc.
KaliVir Immunotherapeutics
Sotio Biotech Inc.
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
ViroMissile, Inc.
Tizona Therapeutics, Inc
Jonsson Comprehensive Cancer Center
MacroGenics
Fusion Pharmaceuticals Inc.
Innate Pharma
OncoNano Medicine, Inc.
City of Hope Medical Center
HiFiBiO Therapeutics
TScan Therapeutics, Inc.
Incyte Corporation
Actym Therapeutics, Inc.
Pfizer
Arcus Biosciences, Inc.
University of Virginia
Incyte Corporation
Turnstone Biologics, Corp.
Revolution Medicines, Inc.
Seagen Inc.
Vincerx Pharma, Inc.
AstraZeneca
Astellas Pharma Inc
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc
Xencor, Inc.
Gene Surgery LLC
Pliant Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
University of Florida
Fate Therapeutics
Xencor, Inc.
Prelude Therapeutics
Quadriga Biosciences, Inc.
Repertoire Immune Medicines
Xencor, Inc.
Revolution Medicines, Inc.
Suzhou BlueHorse Therapeutics Co., Ltd.
Pfizer
Incyte Corporation
Incyte Corporation
Abramson Cancer Center at Penn Medicine
University of Southern California
Rutgers, The State University of New Jersey
National Institutes of Health Clinical Center (CC)